SRPT has been in the news 750% more than usual
Jun 16, 2025, 2:32 PM
8.29%
What does SRPT do
Sarepta Therapeutics, based in Cambridge, Massachusetts, focuses on RNA-targeted therapeutics for rare diseases, particularly Duchenne muscular dystrophy, and has developed four approved products. The company employs 1,314 people and has about 40 programs in its pipeline.
SRPT has been in the news recently: Sarepta Therapeutics, Inc. experienced a significant 40% decline in its stock price during premarket trading due to safety concerns regarding its Duchenne muscular dystrophy gene therapy, Elevidys. Meanwhile, U.S. stock futures showed a positive trend, with the Dow futures rising over 150 points.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.